National Institute on Drug Abuse; Notice of Closed Meeting, 19499 [2013-07424]

Download as PDF Federal Register / Vol. 78, No. 62 / Monday, April 1, 2013 / Notices Contact Person: Martin H. Goldrosen, Ph.D., Director, Division of Extramural Activities, National Center for Complementary and Alternative Medicine, NIH, 6707 Democracy Blvd., Ste. 401, Bethesda, MD 20892–5475, (301) 594–2014, goldrosm@mail.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit. Information is also available on the Institute’s/Center’s home page: nccam.nih.gov/about/naccam/, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.213, Research and Training in Complementary and Alternative Medicine, National Institutes of Health, HHS) Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Minna Liang, Ph.D., Scientific Review Officer, Grants Review Branch, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4226, MSC 9550, Bethesda, MD 20892–9550, 301– 435–1432, liangm@nida.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: March 26, 2013. Anna Snouffer, Deputy Director, Office of Federal Advisory Committee Policy. National Institutes of Health BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health pmangrum on DSK3VPTVN1PROD with NOTICES National Institute on Drug Abuse; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 USC, as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel PAR– 12–297: Mechanism for Time-Sensitive Drug Abuse Research. Date: April 9, 2013. Time: 12:00 p.m. to 2:00 p.m. 15:34 Mar 29, 2013 Jkt 229001 [FR Doc. 2013–07424 Filed 3–29–13; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institute on Drug Abuse; Notice of Closed Meeting [FR Doc. 2013–07421 Filed 3–29–13; 8:45 am] VerDate Mar<15>2010 Dated: March 26, 2013. Anna Snouffer, Deputy Director, Office of Federal Advisory Committee Policy. Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 USC, as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Profile Screening and Predictive Toxicology (8909). Date: April 29, 2013. Time: 10:00 a.m. to 12:00 p.m. Agenda: To review and evaluate contract proposals. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Lyle Furr, Contract Review Specialist, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4227, MSC 9550, 6001 Executive Boulevard, Bethesda, MD 20892– 9550, (301) 435–1439, lf33c.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 19499 Addiction Research Programs, National Institutes of Health, HHS) Dated: March 26, 2013. Anna Snouffer, Deputy Director, Office of Federal Advisory Committee Policy. [FR Doc. 2013–07423 Filed 3–29–13; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Request for Information: The National Toxicology Program Requests Information On Assays and Approaches Useful for Screening Compounds for Potential Neurotoxicity SUMMARY: The National Toxicology Program (NTP) requests information on medium- or high-throughput technologies/assay systems, which allow for the batch screening of compounds (e.g., 25–50) in biochemicalor cell-based assays or alternative (nonrodent) animal models, that might be used to prioritize compounds for in vivo neurotoxicity testing. DATES: The deadline for receipt of information is May 1, 2013. ADDRESSES: Information may be submitted electronically or as printed copy. Electronic submissions: Email to barbourp@niehs.nih.gov. Print submissions: Send 4 copies to Patrick J. Barbour, Contract Specialist, National Institute of Environmental Health Sciences (NIEHS), P.O. Box 12233 (MD K1–05), Research Triangle Park, NC 27709. Courier address: 530 Davis Drive, Keystone Building, Room 1059, Morrisville, NC 27560. FOR FURTHER INFORMATION CONTACT: Patrick J. Barbour, Contract Specialist, NIEHS, P.O. Box 12233 (MD K1–05), Research Triangle Park, NC 27709. Courier address: 530 Davis Drive, Keystone Building, Room 1059, Morrisville, NC 27560. Email: barbourp@niehs.nih.gov. SUPPLEMENTARY INFORMATION: Background For the purposes of this request for information (RFI), neurotoxicity means adverse outcomes to the nervous system resulting from exposure during any life stage. Special emphasis is placed on identifying assay systems that interrogate cellular and molecular events that are critical to the development and/or function of the nervous system. The NTP is also interested in receiving E:\FR\FM\01APN1.SGM 01APN1

Agencies

[Federal Register Volume 78, Number 62 (Monday, April 1, 2013)]
[Notices]
[Page 19499]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-07424]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
USC, as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable materials, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel PAR-12-297: Mechanism for Time-Sensitive Drug Abuse 
Research.
    Date: April 9, 2013.
    Time: 12:00 p.m. to 2:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852, (Telephone Conference 
Call).
    Contact Person: Minna Liang, Ph.D.,
    Scientific Review Officer, Grants Review Branch, Office of 
Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 
6001 Executive Blvd., Room 4226, MSC 9550, Bethesda, MD 20892-9550, 
301-435-1432, liangm@nida.nih.gov.
    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)

    Dated: March 26, 2013.
Anna Snouffer,
Deputy Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2013-07424 Filed 3-29-13; 8:45 am]
BILLING CODE 4140-01-P